S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
Log in

Synthetic Biologics Stock Price, Forecast & Analysis (NYSEAMERICAN:SYN)

$0.39
-0.01 (-2.50 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$0.39
Now: $0.39
$0.40
50-Day Range N/A
52-Week Range
$0.37
Now: $0.39
$0.91
Volume111,325 shs
Average Volume169,299 shs
Market Capitalization$6.55 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthetic Biologics, Inc, a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees13
Market Cap$6.55 million
Next Earnings Date2/26/2020 (Estimated)
OptionableNot Optionable

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.


Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?

Synthetic Biologics's stock reverse split on the morning of Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics Inc (NYSEAMERICAN:SYN) issued its quarterly earnings results on Monday, November, 4th. The company reported ($0.31) EPS for the quarter. View Synthetic Biologics' Earnings History.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Synthetic Biologics.

What price target have analysts set for SYN?

1 analysts have issued 12-month target prices for Synthetic Biologics' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Synthetic Biologics' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,438.5% from the stock's current price. View Analyst Price Targets for Synthetic Biologics.

What is the consensus analysts' recommendation for Synthetic Biologics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthetic Biologics.

What are Wall Street analysts saying about Synthetic Biologics stock?

Here are some recent quotes from research analysts about Synthetic Biologics stock:
  • 1. According to Zacks Investment Research, "Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. " (4/25/2019)
  • 2. HC Wainwright analysts commented, "We are lowering our price target to $6, from $38, as a result of pushing back timelines, a possible smaller indication for ribaxamase at launch, and increased share count due to capital raises. We base our $6 price target on probability-adjusted revenue forecasts for ribaxamase in the prevention of CDI and SYN-010 for the treatment of IBS-C. We use the net present value of our revenue forecast through 2028, apply a 35% probability of success (POS) for ribaxamase in CDI, a 25% POS for the early stage pipeline, and a 3x price/sales multiple to arrive at our price target." (11/20/2018)

Has Synthetic Biologics been receiving favorable news coverage?

News headlines about SYN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Synthetic Biologics earned a news impact score of 0.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Synthetic Biologics.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 172,100 shares, an increase of 66.8% from the September 30th total of 103,200 shares. Based on an average daily volume of 83,300 shares, the short-interest ratio is presently 2.1 days. Approximately 1.1% of the shares of the company are short sold. View Synthetic Biologics' Current Options Chain.

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the folowing people:
  • Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 58)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Vince Wacher, Head of Product and Corp. Devel.
  • Dr. Michael Kaleko, Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.39.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $6.55 million. Synthetic Biologics employs 13 workers across the globe.View Additional Information About Synthetic Biologics.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is http://www.syntheticbiologics.com/.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.


MarketBeat Community Rating for Synthetic Biologics (NYSEAMERICAN SYN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  331 (Vote Underperform)
Total Votes:  746
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel